JP2020200352A5 - - Google Patents

Download PDF

Info

Publication number
JP2020200352A5
JP2020200352A5 JP2020161995A JP2020161995A JP2020200352A5 JP 2020200352 A5 JP2020200352 A5 JP 2020200352A5 JP 2020161995 A JP2020161995 A JP 2020161995A JP 2020161995 A JP2020161995 A JP 2020161995A JP 2020200352 A5 JP2020200352 A5 JP 2020200352A5
Authority
JP
Japan
Prior art keywords
composition
subject
use according
apoe4
mmse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020161995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020200352A (ja
JP7128536B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020200352A publication Critical patent/JP2020200352A/ja
Publication of JP2020200352A5 publication Critical patent/JP2020200352A5/ja
Priority to JP2022128786A priority Critical patent/JP2022145949A/ja
Application granted granted Critical
Publication of JP7128536B2 publication Critical patent/JP7128536B2/ja
Priority to JP2025023627A priority patent/JP2025065545A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020161995A 2015-09-10 2020-09-28 特定の患者集団において神経変性障害を処置する方法 Active JP7128536B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022128786A JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法
JP2025023627A JP2025065545A (ja) 2015-09-10 2025-02-17 特定の患者集団において神経変性障害を処置する方法

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US62/216,404 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US62/290,287 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US62/302,027 2016-03-01
US201662365809P 2016-07-22 2016-07-22
US62/365,809 2016-07-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018512564A Division JP6789579B2 (ja) 2015-09-10 2016-09-09 特定の患者集団において神経変性障害を処置する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022128786A Division JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法

Publications (3)

Publication Number Publication Date
JP2020200352A JP2020200352A (ja) 2020-12-17
JP2020200352A5 true JP2020200352A5 (https=) 2021-04-30
JP7128536B2 JP7128536B2 (ja) 2022-08-31

Family

ID=58240195

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018512564A Active JP6789579B2 (ja) 2015-09-10 2016-09-09 特定の患者集団において神経変性障害を処置する方法
JP2020161995A Active JP7128536B2 (ja) 2015-09-10 2020-09-28 特定の患者集団において神経変性障害を処置する方法
JP2022128786A Pending JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法
JP2025023627A Pending JP2025065545A (ja) 2015-09-10 2025-02-17 特定の患者集団において神経変性障害を処置する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018512564A Active JP6789579B2 (ja) 2015-09-10 2016-09-09 特定の患者集団において神経変性障害を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022128786A Pending JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法
JP2025023627A Pending JP2025065545A (ja) 2015-09-10 2025-02-17 特定の患者集団において神経変性障害を処置する方法

Country Status (21)

Country Link
US (3) US11191742B2 (https=)
EP (2) EP4275750B1 (https=)
JP (4) JP6789579B2 (https=)
KR (2) KR102547164B1 (https=)
CN (3) CN108289870A (https=)
AU (1) AU2016319107B2 (https=)
CA (1) CA2997376C (https=)
DK (1) DK3347002T3 (https=)
ES (1) ES2952727T3 (https=)
FI (1) FI3347002T3 (https=)
HR (1) HRP20230809T1 (https=)
HU (1) HUE062511T2 (https=)
LT (1) LT3347002T (https=)
MD (1) MD3347002T2 (https=)
MX (2) MX392677B (https=)
PL (1) PL3347002T3 (https=)
PT (1) PT3347002T (https=)
RS (1) RS64481B1 (https=)
SI (1) SI3347002T1 (https=)
SM (1) SMT202300250T1 (https=)
WO (1) WO2017044840A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102645633B1 (ko) 2014-03-21 2024-03-11 알제온, 인크. 신경학적 장애를 치료하는 방법
EP4275750B1 (en) * 2015-09-10 2026-05-06 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
CN114805211B (zh) 2017-03-21 2024-08-23 润佳(苏州)医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
SI3829568T1 (sl) * 2018-08-01 2024-02-29 Alzheon, Inc. Derivati sulfopropanojske kisline za zdravljenje nevrodegenerativnih motenj
HUE070101T2 (hu) * 2018-08-01 2025-05-28 Alzheon Inc 3-Szulfopropánsav neurodegeneratív rendellenességek kezelésére
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
UA129160C2 (uk) * 2019-06-17 2025-01-29 Алзхеон, Інк. Спосіб лікування хвороби альцгеймера
CN116059192B (zh) 2019-11-13 2024-10-29 润佳(苏州)医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
JP2024542844A (ja) * 2021-12-09 2024-11-15 アルツェオン・インコーポレーテッド アルツハイマー病の処置に使用されるalz-801
WO2023150381A1 (en) * 2022-02-07 2023-08-10 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
JP3265577B2 (ja) 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白eの4型イソ型の測定法
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
SG145784A1 (en) 2003-08-11 2008-09-29 California Inst Of Techn Microfluidic large scale integration
CA2611586A1 (en) 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
DK2089417T3 (en) * 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
KR101450356B1 (ko) 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 n-(메틸)-1h-피라졸-3-아민, n-(메틸)-피리딘-2-아민 및 n-(메틸)-티아졸-2-아민 유도체
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20120009125A1 (en) 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
ES2705027T3 (es) * 2010-08-19 2019-03-21 Buck Institute For Age Res Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
CA2938466C (en) * 2014-02-08 2021-11-02 Genentech, Inc. Methods of treating alzheimer's disease
KR102645633B1 (ko) 2014-03-21 2024-03-11 알제온, 인크. 신경학적 장애를 치료하는 방법
EP4275750B1 (en) * 2015-09-10 2026-05-06 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population

Similar Documents

Publication Publication Date Title
JP2020200352A5 (https=)
KR102795284B1 (ko) 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법
Healy et al. An association between recurrent oro‐genital ulceration and non‐steroidal anti‐inflammatory drugs
JP2018526407A5 (https=)
CN1681486A (zh) 莫达非尼药物剂型
FI3347002T3 (fi) Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa
JP2020535227A5 (https=)
US10456393B2 (en) Treating pain in patients with hepatic impairment
BR112020008128A2 (pt) comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos
JP2024507367A5 (https=)
US20100035927A1 (en) Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia
JP2025111439A (ja) トラピジルを使用した認知障害の治療
WO2009123206A1 (ja) 経口医薬組成物
Smith et al. Lesch-Nyhan syndrome: a case report
JP2023531930A5 (https=)
JP2015521647A5 (https=)
RU2237475C1 (ru) Комбинированный препарат для устранения симптомов простудных заболеваний и гриппа (варианты)
JP2002348240A (ja) 医薬組成物
JP2012031141A (ja) 骨髄異形性症候群を治療するための組成物および方法
JP3502951B2 (ja) 高脂血症治療剤
WO2023066330A1 (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
EP2184284B1 (en) Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
WO2018192469A1 (en) Inhibitors of fabp4 and methods of treating arthritis
JP2004002362A (ja) くしゃみ抑制組成物
US20110301199A1 (en) Compositions and methods for treating myelodysplastic syndrome